Is there a role for immunotherapy in osteosarcoma?

David M. Loeb

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

With the introduction of effective systemic chemotherapy, the prognosis for patients with osteosarcoma has improved dramatically. Estimates of overall survival for osteosarcoma patients prior to 1975 ranged from 5 to 20%, even for patients with localized disease of the extremity treated with amputation. The majority of these patients eventually developed pulmonary metastases and succumbed to their disease. The introduction of effective chemotherapy has dramatically improved the outcome of patients with localized disease, but has not altered the survival of patients with metastatic disease. Moreover, there has been little, if any, improvement in the outcomes of patients with localized disease since the mid-1980s. This has led to the investigation of other treatment approaches, including immunotherapy. Coincident with the initial development of chemotherapy, there were early attempts at immunotherapy. These met with little success. Subsequent approaches to harnessing the immune system have yielded more encouraging results. This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
Pages447-457
Number of pages11
Volume152
DOIs
StatePublished - 2009

Publication series

NameCancer Treatment and Research
Volume152
ISSN (Print)09273042

Fingerprint

Osteosarcoma
Immunotherapy
Drug Therapy
Survival
Amputation
Immune System
Extremities
Neoplasm Metastasis
Lung
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Loeb, D. M. (2009). Is there a role for immunotherapy in osteosarcoma? In Cancer Treatment and Research (Vol. 152, pp. 447-457). (Cancer Treatment and Research; Vol. 152). https://doi.org/10.1007/978-1-4419-0284-9_25

Is there a role for immunotherapy in osteosarcoma? / Loeb, David M.

Cancer Treatment and Research. Vol. 152 2009. p. 447-457 (Cancer Treatment and Research; Vol. 152).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Loeb, DM 2009, Is there a role for immunotherapy in osteosarcoma? in Cancer Treatment and Research. vol. 152, Cancer Treatment and Research, vol. 152, pp. 447-457. https://doi.org/10.1007/978-1-4419-0284-9_25
Loeb DM. Is there a role for immunotherapy in osteosarcoma? In Cancer Treatment and Research. Vol. 152. 2009. p. 447-457. (Cancer Treatment and Research). https://doi.org/10.1007/978-1-4419-0284-9_25
Loeb, David M. / Is there a role for immunotherapy in osteosarcoma?. Cancer Treatment and Research. Vol. 152 2009. pp. 447-457 (Cancer Treatment and Research).
@inproceedings{6f0e820462084060836e3611392aa26a,
title = "Is there a role for immunotherapy in osteosarcoma?",
abstract = "With the introduction of effective systemic chemotherapy, the prognosis for patients with osteosarcoma has improved dramatically. Estimates of overall survival for osteosarcoma patients prior to 1975 ranged from 5 to 20{\%}, even for patients with localized disease of the extremity treated with amputation. The majority of these patients eventually developed pulmonary metastases and succumbed to their disease. The introduction of effective chemotherapy has dramatically improved the outcome of patients with localized disease, but has not altered the survival of patients with metastatic disease. Moreover, there has been little, if any, improvement in the outcomes of patients with localized disease since the mid-1980s. This has led to the investigation of other treatment approaches, including immunotherapy. Coincident with the initial development of chemotherapy, there were early attempts at immunotherapy. These met with little success. Subsequent approaches to harnessing the immune system have yielded more encouraging results. This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma.",
author = "Loeb, {David M.}",
year = "2009",
doi = "10.1007/978-1-4419-0284-9_25",
language = "English (US)",
isbn = "9781441902832",
volume = "152",
series = "Cancer Treatment and Research",
pages = "447--457",
booktitle = "Cancer Treatment and Research",

}

TY - GEN

T1 - Is there a role for immunotherapy in osteosarcoma?

AU - Loeb, David M.

PY - 2009

Y1 - 2009

N2 - With the introduction of effective systemic chemotherapy, the prognosis for patients with osteosarcoma has improved dramatically. Estimates of overall survival for osteosarcoma patients prior to 1975 ranged from 5 to 20%, even for patients with localized disease of the extremity treated with amputation. The majority of these patients eventually developed pulmonary metastases and succumbed to their disease. The introduction of effective chemotherapy has dramatically improved the outcome of patients with localized disease, but has not altered the survival of patients with metastatic disease. Moreover, there has been little, if any, improvement in the outcomes of patients with localized disease since the mid-1980s. This has led to the investigation of other treatment approaches, including immunotherapy. Coincident with the initial development of chemotherapy, there were early attempts at immunotherapy. These met with little success. Subsequent approaches to harnessing the immune system have yielded more encouraging results. This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma.

AB - With the introduction of effective systemic chemotherapy, the prognosis for patients with osteosarcoma has improved dramatically. Estimates of overall survival for osteosarcoma patients prior to 1975 ranged from 5 to 20%, even for patients with localized disease of the extremity treated with amputation. The majority of these patients eventually developed pulmonary metastases and succumbed to their disease. The introduction of effective chemotherapy has dramatically improved the outcome of patients with localized disease, but has not altered the survival of patients with metastatic disease. Moreover, there has been little, if any, improvement in the outcomes of patients with localized disease since the mid-1980s. This has led to the investigation of other treatment approaches, including immunotherapy. Coincident with the initial development of chemotherapy, there were early attempts at immunotherapy. These met with little success. Subsequent approaches to harnessing the immune system have yielded more encouraging results. This chapter will review these various approaches, highlighting the role that immunotherapy might play in the multi-modality treatment of localized and metastatic osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=77953673602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953673602&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0284-9_25

DO - 10.1007/978-1-4419-0284-9_25

M3 - Conference contribution

SN - 9781441902832

VL - 152

T3 - Cancer Treatment and Research

SP - 447

EP - 457

BT - Cancer Treatment and Research

ER -